United States Hospital Acquired Disease Testing Market

Market Overview:

The United States hospital acquired disease testing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hospital-acquired diseases (HADs) are infections acquired during hospital visits or stays. They are commonly known as nosocomial infections and are caused by bacterial, fungal and viral pathogens. Some of the commonly used HAD testing techniques include the complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, urinalysis and analysis of the infected area, blood, urine and other body fluids. These techniques assist in the diagnosis of conditions such as urinary tract infections (UTI), surgical site infections (SSI) and hospital-acquired pneumonia (HAP).

The increasing prevalence of hospital acquired infections (HAIs) and diseases in the United States is one of the key factors driving the growth of the market. Furthermore, the increasing awareness regarding the benefits of the early detection of these diseases is providing a boost to the market growth. Healthcare providers are also emphasizing on maintaining adequate hygiene in hospitals, clinics and other healthcare centers to minimize the risks of HADs. Additionally, various technological innovations, such as the development of microarrays, polymerase chain reaction (PCR), solid phase hybridization and real-time location systems (RTLSs) for preventing and monitoring HAIs, are contributing to the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the United States hospital acquired disease testing market, along with forecasts at the country and regional level from 2021-2026. Our report has categorized the market based on indication.

Breakup by Indication:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others
   

Breakup by Region:

• Northeast
• Midwest
• South
• West
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Key Questions Answered in This Report:

• How has the United States hospital acquired disease testing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the United States hospital acquired disease testing market?
• What are the key regional markets?
• What is the breakup of the market based on the indication?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the United States hospital acquired disease testing market and who are the key players?
• What is the degree of competition in the industry?